Bacterial prostatitis: treatment with carbenicillin indanyl sodium.
The efficacy and safety of carbenicillin indanyl sodium were evaluated in 16 patients with acute or chronic bacterial prostatitis. Each patient received carbenicillin indanyl sodium (Geocillin) tablets, at a dosage of two 500 mg tablets (each tablet equivalent to 382 mg of carbenicillin) four times daily for either 14 days (acute patients) or 28 days (chronic patients). Clinical and bacteriologic success rates, based upon 4 week post therapy followup, were 93 per cent and 75 per cent respectively. There were no adverse reactions. Results with cephalexin in a concurrently treated alternative therapy group were generally unsatisfactory. Further evaluations of carbenicillin indanyl sodium in this treatment of resistant populations are clearly warranted.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002228:Carbenicillin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002506:Cephalexin / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology
C100244:carbenicillin indanyl; D002228:Carbenicillin; D002506:Cephalexin